Tussanil DH Tablets

What do you feel about the cost of the medicine? Is it expensive?
advertisement

Tussanil DH Tablets uses

Tussanil DH Tablets consists of Guaifenesin, Hydrocodone Tartrate, Phenylpropanolamine Hydrochloride.

Guaifenesin:


An expectorant that also has some muscle relaxing action. It is used in many cough preparations.

Indication: Used to assist the expectoration of phlegm from the airways in acute respiratory tract infections.

Tussanil DH Tablets (Guaifenesin) is an expectorant which increases the output of phlegm (sputum) and bronchial secretions by reducing adhesiveness and surface tension. The increased flow of less viscous secretions promotes ciliary action and changes a dry, unproductive cough to one that is more productive and less frequent. By reducing the viscosity and adhesiveness of secretions, Tussanil DH Tablets (Guaifenesin) increases the efficacy of the mucociliary mechanism in removing accumulated secretions from the upper and lower airway.

Hydrocodone Tartrate:


1 INDICATIONS AND USAGE

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is indicated for symptomatic relief of cough and to loosen mucus associated with the common cold.

Important Limitations of Use:

Not indicated for pediatric patients under 18 years of age .

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is a combination product containing an opioid antitussive and expectorant indicated for:

  • Symptomatic relief of cough and to loosen mucus associated with the common cold.

Important Limitations of Use:

Not indicated for pediatric patients under 18 years of age. ( 8.4)

2 DOSAGE AND ADMINISTRATION

Adults and adolescents 18 years of age and older: 10 mL every 4 to 6 hours, not to exceed 6 doses in 24 hours. ( 2.1)

Measure Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with an accurate milliliter measuring device. ( 5.10)

2.1 Recommended dosage

Adults and adolescents 18 years of age and older: 10 mL every 4 to 6 hours, not to exceed 6 doses (60 mL) in 24 hours.

Administer Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution by the oral route only. Measure Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with an accurate milliliter measuring device. Do not use a household teaspoon to measure the dose .

advertisement

3 DOSAGE FORMS AND STRENGTHS

Oral Solution:

Each 5 mL contains Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg .

Oral Solution: Each 5 mL contains Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.( 3)

4 CONTRAINDICATIONS

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is contraindicated in:

  • Patients with known hypersensitivity to Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate, guaifenesin, or any of the inactive ingredients of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution.
  • Patients receiving MAOI therapy or within 14 days of stopping such therapy .
  • Patients with known hypersensitivity to Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate, guaifenesin, or any of the inactive ingredients of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution. ( 4)
  • Patients receiving monoamine oxidase inhibitor (MAOI) therapy or within 14 days of stopping such therapy. ( 4)

5 WARNINGS AND PRECAUTIONS

  • Dose-related respiratory depression: Use with caution.
  • Drug Dependence: Prescribe with caution that is appropriate to the use of other opioids. ( 5.3)
  • Head injury and increased intracranial pressure: Avoid in patients with head injury, intracranial lesions or increased intracranial pressure. ( 5.4)
  • Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating machinery. ( 5.5)
  • Acute abdominal conditions: Use with caution in patients with acute abdominal conditions. ( 5.6)
  • Coexisting conditions: Use with caution in patients with diabetes, thyroid disease, Addison’s disease, prostatic hypertrophy, or urethral stricture, or asthma. ( 5.11)

5.1 Risks from Concomitant Use with Benzodiazepines or other CNS Depressants

Concomitant use of opioids, including Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, with benzodiazepines, or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Because of these risks, avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol .

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol.

Advise both patients and caregivers about the risks of respiratory depression and sedation if Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is used with benzodiazepines, alcohol, or other CNS depressants .

5.2 Respiratory Depression

Tussanil DH Tablets bitartrate, one of the active ingredients in Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, produces dose-related respiratory depression by directly acting on brain stem respiratory centers. Overdose of Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate in adults has been associated with fatal respiratory depression, and the use of Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate in children less than 6 years of age has been associated with fatal respiratory depression. Exercise caution when administering Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution because of the potential for respiratory depression. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated .

5.3 Drug Dependence

Tussanil DH Tablets (Hydrocodone Tartrate) can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution. Prescribe and administer Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with the same degree of caution appropriate to the use of other opioid drugs .

5.4 Head Injury and Increased Intracranial Pressure

The respiratory depression effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of Tussanil DH Tablets Oral Solution should be avoided in these patients.

5.5 Activities Requiring Mental Alertness

Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate, one of the active ingredients in Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution. Concurrent use of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur.

5.6 Acute Abdominal Conditions

Tussanil DH Tablets Oral Solution should be used with caution in patients with acute abdominal conditions since the administration of Tussanil DH Tablets (Hydrocodone Tartrate) may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of other anticholinergics with Tussanil DH Tablets (Hydrocodone Tartrate) may produce paralytic ileus .

5.7 Co-administration with Anticholinergics

The concurrent use of anticholinergics with Tussanil DH Tablets (Hydrocodone Tartrate) may produce paralytic ileus. Exercise caution when using Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution in patients taking anticholinergic medications .

5.8 Co-administration with MAOIs or Tricyclic Antidepressants

Tussanil DH Tablets Oral Solution should not be used in patients receiving MAOI therapy or within 14 days of stopping such therapy. The use of MAOIs or tricyclic antidepressants with Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate may increase the effect of either the antidepressant or Tussanil DH Tablets (Hydrocodone Tartrate) .

5.9 Persistent Cough

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution should not be used in patients with a persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema, or where cough is accompanied by excessive phlegm (mucus).

5.10 Dosing

Patients should be advised to measure Tussanil DH Tablets Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions . Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose.

5.11 Coexisting Conditions

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution should be used with caution in patients with diabetes, thyroid disease, Addison's disease, prostatic hypertrophy or urethral stricture, and asthma.

5.12 Renal Impairment

Tussanil DH Tablets Oral Solution should be used with caution in patients with severe renal impairment.

5.13 Hepatic Impairment

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution should be used with caution in patients with severe hepatic impairment .

advertisement

6 ADVERSE REACTIONS

Use of Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate is associated with the following:

  • Respiratory depression
  • Drug dependence
  • Increased intracranial pressure
  • Decreased mental alertness with impaired mental and/or physical abilities
  • Paralytic ileus

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most common adverse reactions experienced by subjects taking a single dose of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution in the clinical setting include the following: Central Nervous System: headache, dizziness, sedation (somnolence); Gastrointestinal System: nausea, diarrhea; Cardiovascular System: decreased blood pressure; Vascular System: hot flush.

The most common adverse reactions of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution include:

Dizziness, headache, sedation, nausea, and decreased blood pressure. ( 6)

To report SUSPECTED ADVERSE REACTIONS, contact ABER Pharmaceuticals, LLC. at tel: 1-855-461-5102; www.obredon.com or FDA at 1-800-FDA-1088; www.fda.gov/medwatch.

advertisement

7 DRUG INTERACTIONS

No specific interaction studies have been conducted with Tussanil DH Tablets Oral Solution.

  • Opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants (including alcohol): Avoid using with Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution; may exhibit additive CNS depression. ( 7.1)
  • MAO inhibitors (MAOIs) or tricyclic antidepressants: Do not use. May increase the effect of either the antidepressant or Tussanil DH Tablets (Hydrocodone Tartrate). ( 7.2)
  • Anticholinergic drugs: Use with caution in order to avoid paralytic ileus and excessive anticholinergic effects. ( 7.3)

7.1 Benzodiazepines, Opioids, Antihistamines, Antipsychotics, Anti-anxiety Agents, or Other CNS Depressants (Including Alcohol)

The use of benzodiazepines, opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants concomitantly with Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution may cause an additive CNS depressant effect, profound sedation, respiratory depression, coma, and death and should be avoided .

7.2 MAO Inhibitors or Tricyclic Antidepressants

Do not prescribe Tussanil DH Tablets Oral Solution if the patient is taking a prescription MAOI (i.e., certain drugs used for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with Tussanil DH Tablets (Hydrocodone Tartrate) preparations may increase the effect of either the antidepressant or Tussanil DH Tablets (Hydrocodone Tartrate) .

7.3 Anticholinergic Drugs

Tussanil DH Tablets (Hydrocodone Tartrate) should be administered cautiously to persons receiving anticholinergic drugs in order to avoid paralytic ileus and excessive anticholinergic effects .

advertisement

8 USE IN SPECIFIC POPULATIONS

  • Renal Impairment: Use with caution in patients with severe renal impairment.
  • Hepatic Impairment: Use with caution in patients with severe hepatic impairment. ( 8.7)

8.1 Pregnancy

Teratogenic Effects: Pregnancy Category C

There are no adequate and well controlled studies of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution in pregnant women. Reproductive toxicity studies have not been conducted with Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution; however, studies are available with an individual active ingredient or related active ingredient. Tussanil DH Tablets (Hydrocodone Tartrate) was teratogenic in hamsters. Codeine, an opiate related to Tussanil DH Tablets (Hydrocodone Tartrate), increased resorptions and decreased fetal weight in rats. Because animal reproduction studies are not always predictive of human response, Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution should be used during pregnancy only if the benefit justifies the potential risk to the fetus.

Tussanil DH Tablets (Hydrocodone Tartrate):

Tussanil DH Tablets (Hydrocodone Tartrate) has been shown to be teratogenic in hamsters when given in a dose approximately 27 times the maximum recommended human daily dose (MRHDD) (on a mg/m 2 basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to Tussanil DH Tablets (Hydrocodone Tartrate). In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 40 times the MRHDD of Tussanil DH Tablets (Hydrocodone Tartrate) (on a mg/m 2 basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity. In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 20 and 100 times, respectively, the MRHDD of Tussanil DH Tablets (Hydrocodone Tartrate) (on a mg/m 2 basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects.

Nonteratogenic Effects: Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.

8.2 Labor and Delivery

As with all opioids, administration of Tussanil DH Tablets Oral Solution to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.

8.3 Nursing Mothers

Caution should be exercised when Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is administered to nursing mothers. Tussanil DH Tablets (Hydrocodone Tartrate) is known to be excreted in human milk. No studies have been performed to determine if guaifenesin is excreted into breastmilk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of Tussanil DH Tablets Oral Solution in pediatric patients under 18 years of age has not been established. The use of Tussanil DH Tablets (Hydrocodone Tartrate) in children less than 6 years of age is associated with fatal respiratory depression .

8.5 Geriatric Use

Clinical studies have not been conducted with Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution in geriatric populations. Other reported clinical experience with the individual active ingredients of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6 Renal Impairment

Tussanil DH Tablets Oral Solution should be given with caution in patients with severe impairment of renal function.

8.7 Hepatic Impairment

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution should be given with caution in patients with severe impairment of hepatic function.

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Tussanil DH Tablets Oral Solution is a Schedule II controlled prescription containing Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate and should be prescribed and administered with caution.

9.2 Abuse

Tussanil DH Tablets (Hydrocodone Tartrate) can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs.

Abuse of guaifenesin has been linked to the formation of kidney stones composed of the major metabolite β-(2-methoxyphenoxy) lactic acid.

9.3 Dependence

Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of opioids; therefore, Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution should be prescribed and administered with caution.

Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical dependence may develop after a few days of opioid therapy.

10 OVERDOSAGE

No human overdosage data are available for Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution.

Tussanil DH Tablets (Hydrocodone Tartrate):

Overdosage with Tussanil DH Tablets (Hydrocodone Tartrate) is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur.

Guaifenesin:

Overdosage with guaifenesin can cause depression of the central nervous system. While present in polypharmacy overdoses, one case of overdose with only significant levels of guaifenesin has been reported. Symptoms included slurred speech, shallow respirations, reduced heart rate with rhythm sinus bradycardia, followed by asystole.

Treatment of overdosage consists of discontinuation of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdosage or unusual sensitivity to opioids including Tussanil DH Tablets (Hydrocodone Tartrate). Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.

11 DESCRIPTION

Tussanil DH Tablets Oral Solution contains Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate (a centrally-acting opioid antitussive) and guaifenesin (an expectorant).

Each 5 mL dose of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution contains: Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution also contains: artificial raspberry flavor, citric acid, glycerin, methylparaben, potassium citrate, potassium sorbate, propylene glycol, propylparaben, purified water, and saccharin sodium.

11.1 Tussanil DH Tablets (Hydrocodone Tartrate) Bitartrate

Tussanil DH Tablets (Hydrocodone Tartrate) Bitartrate is a centrally-acting opioid antitussive and analgesic. It is affected by light and occurs as fine white crystals or crystalline powder which is derived from the opium alkaloid, thebaine. Its chemical name is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5). It is also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5); and may be represented by the following structural formula:

C 18H 21NO 3 - C 4H 6O 6 - 2½H 2O MW= 494.50

HCB Chemical Structure

11.2 Guaifenesin

Guaifenesin is an expectorant and occurs as a white powder. Its chemical name is 3-(2-methoxyphenoxy)-1,2- propanediol, and may be represented by the following structural formula:

C 10H 14O 4 MW= 198.22

GFN Chemical Structure

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Tussanil DH Tablets is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of Tussanil DH Tablets (Hydrocodone Tartrate) and other opiates is not known; however, Tussanil DH Tablets (Hydrocodone Tartrate) is believed to act directly on the cough center. In excessive doses, Tussanil DH Tablets (Hydrocodone Tartrate) will depress respiration. Tussanil DH Tablets (Hydrocodone Tartrate) can produce miosis, euphoria, and physical and physiological dependence.

Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions.

12.3 Pharmacokinetics

Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate and guaifenesin after single dose administration of 10 mL Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution are equivalent to respective reference solutions of 5 mL Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate (5 mg/5 mL), and 10 mL guaifenesin (200 mg/5 mL).

Tussanil DH Tablets (Hydrocodone Tartrate): Following a single 10 mL oral dose of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution administered to 36 healthy adults (19-74 years), the geometric mean C max and AUC 0-inf for Tussanil DH Tablets (Hydrocodone Tartrate) were 12.6 ng/ml and 80.9 ng·hr/ml, respectively. The median time to maximum concentration for Tussanil DH Tablets (Hydrocodone Tartrate) was about 1.25 hours. Food has no significant effect on the extent of absorption of Tussanil DH Tablets (Hydrocodone Tartrate). The mean plasma half-life of Tussanil DH Tablets (Hydrocodone Tartrate) is approximately 5 hours.

Guaifenesin: Following a single 10 mL oral dose of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution administered to 57 healthy adults (19-74 years), the geometric mean Cmax and AUC0-inf for guaifenesin were 3.7 mcg/ml and 4.2 mcg·hr/ml, respectively. The median time to maximum concentration was about 20 minutes. The effect of food on guaifenesin systemic exposure is not considered to be clinically meaningful. The mean plasma half-life of guaifenesin is approximately 1 hour.

Drug interactions

When guaifenesin and Tussanil DH Tablets (Hydrocodone Tartrate) were administered in combination, the pharmacokinetics for each component were similar to those observed when each component was administered separately.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution; however, published information is available for the individual active ingredients or related active ingredients.

Tussanil DH Tablets (Hydrocodone Tartrate):

Carcinogenicity studies were conducted with codeine, an opiate related to Tussanil DH Tablets (Hydrocodone Tartrate). In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 23 and 65 times, respectively, the MRHDD of Tussanil DH Tablets (Hydrocodone Tartrate) on a mg/m 2 basis).

Guaifenesin:

Carcinogenicity, genotoxicity, or reproductive toxicology studies have not been conducted with guaifenesin

14 CLINICAL STUDIES

Efficacy studies were not conducted with Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution. Efficacy of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is based on demonstration of bioequivalence to the individual comparator products .

16 HOW SUPPLIED/STORAGE AND HANDLING

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is supplied as a clear, raspberry flavored liquid containing 2.5 mg Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate and 200 mg guaifenesin in each 5 mL. It is available in:

White HDPE bottles of 16 fl oz. (473 mL): NDC 69166-523-16 (raspberry flavored)

White HDPE bottles of 4 fl oz. (118 mL): NDC 69166-523-04 (raspberry flavored)

Store solution at 20° to 25°C (68° to 77°F).

Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure.

17 PATIENT COUNSELING INFORMATION


Overdosage

Advise patients not to increase the dose or dosing frequency of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution because serious adverse events such as respiratory depression may occur with overdosage .

Dosing

Advise patients to measure Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose .

Interactions with Benzodiazepines and Other Central Nervous System Depressants

Inform patients and caregivers that potentially fatal additive effects may occur if Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is used with benzodiazepines or other CNS depressants, including alcohol.

Because of this risk, patients should avoid concomitant use of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with benzodiazepines or other CNS depressants, including alcohol .

Activities Requiring Mental Alertness

Advise patients to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution may produce marked drowsiness .

Drug Dependence

Caution patients that Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution contains Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate and can produce drug dependence .

For Medical Information

Contact Medical Affairs Department

Phone: 1-855-461-5102

Manufactured for:

Accelis Pharma

East Windsor, NJ 08520

ACELLIS logo

MEDICATION GUIDE

Tussanil DH Tablets Oral Solution (Oh-brĕ-don Oral Solution)

(hydrocodone bitartrate and guaifenesin) Each 5 mL contains Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg. C-II

What is the most important information I should know about Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

  • Taking Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with benzodiazepines, or other central nervous system depressants, including alcohol can cause severe drowsiness, breathing problems (respiratory depression), coma, and death.
  • Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution can cause you to be drowsy. Do not drive a car or operate machinery until you know how Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution affects you. Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution can slow your thinking and motor skills, and may affect your vision.
  • Women who breastfeed should talk to their healthcare provider before taking Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution.
  • Call your healthcare provider or get emergency medical help right away if anyone taking Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution has any of the symptoms below:
    • increased sleepiness
    • confusion
    • difficulty breathing
    • shallow breathing
    • limpness
    • your baby has difficulty breastfeeding
  • Keep Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and can cause death. If a child accidentally takes Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, get emergency medical help right away.
  • Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution can cause serious side effects, including death.
  • Take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution exactly as prescribed by your healthcare provider. If you take the wrong dose of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, you could overdose and die.
  • Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is not for children under 18 years of age.

What is Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

  • Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is a prescription medicine used to treat a cough and to loosen mucus associated with the common cold, in patients 18 years and older. Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution contains two medicines, Tussanil DH Tablets (Hydrocodone Tartrate) and guaifenesin. Tussanil DH Tablets (Hydrocodone Tartrate) is a narcotic cough suppressant. Guaifenesin is an expectorant.
  • Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is a federal controlled substance (C-II) because it contains Tussanil DH Tablets (Hydrocodone Tartrate) that can be abused or lead to dependence. Keep Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution in a safe place to prevent misuse and abuse. Selling or giving away Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.
  • Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is not for children under 18 years of age. It is not known if Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution is safe and effective in children.

Who should not take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

  • Do not take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution if you are allergic to any of the ingredients in Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution. See the end of this Medication Guide for a complete list of ingredients. You may have an increased risk of having an allergic reaction to Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution if you are allergic to certain other opioid medicines.
  • Do not take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution if you take a medicine for depression called a Monoamine Oxidase Inhibitor (MAOI)
    • Do not take an MAOI within 14 days after you stop taking Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution.
    • Do not start Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution if you stopped taking an MAOI in the last 14 days.

Before you take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, tell your healthcare provider about all of your medical conditions, including if you:

    • have a drug dependence
    • have lung or breathing problems
    • have had a head injury
    • have pain in your stomach-area (abdomen)
    • have a history of severe or persistent cough
    • have prostate problems
    • have problems with your urinary tract(urethral stricture)
    • plan to have surgery
    • drink alcohol
    • have kidney or liver problems
    • have diabetes
    • have thyroid problems, such as hypothyroidism
    • are pregnant or plan to become pregnant. It is not known if Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution will harm your unborn baby. You and your healthcare provider should decide if you should take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution while you are pregnant.
    • are breastfeeding or plan to breastfeed. It is not known if Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution passes into your breast milk. You and your healthcare provider should decide if you will take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution with certain other medicines can cause side effects or affect how well Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider.

Especially tell your healthcare provider if you:

  • take pain medicines such as narcotics
  • take cold or allergy medicines that contain antihistamines or cough suppressants
  • take medicines for mental illness (anti-psychotics, anti-anxiety)
  • drink alcohol
  • take medicines for depression, including monoamine oxidase inhibitors (MAOIs) and tricyclics
  • The use of MAOIs or tricyclic antidepressants with Tussanil DH Tablets (Hydrocodone Tartrate) bitartrate may increase the effect of either the antidepressant or Tussanil DH Tablets (Hydrocodone Tartrate).

How should I take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

  • Take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution exactly as your healthcare provider tells you to take it.
  • Your healthcare provider will tell you how much Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution to take and when to take it. Do not change your dose without talking to your healthcare provider.
  • Administer Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution by the oral route only.
  • Ask your pharmacist to give you a measuring device to help you measure the correct amount of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution. Do not use a household teaspoon to measure your medicine. You may accidently take too much.
  • If you take too much Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

  • Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution can cause you to be drowsy. Do not drive a car or operate machinery while you take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution until you know how it affects you.
  • Avoid drinking alcohol while taking Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution. Drinking alcohol can increase your chances of having serious side effects.

What are the possible side effects of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution may cause serious side effects, including:

  • See “What is the most important information I should know about Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?”
  • breathing problems (respiratory depression) which can lead to death. Call your healthcare provider or get emergency treatment right away if you are sleeping more than usual, have shallow or slow breathing, or confusion.
  • Physical dependence or abuse. Take Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution exactly as your healthcare provider tells you to take it. Stopping Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution suddenly could cause withdrawal symptoms.
  • Bowel problems including constipation or stomach pain.

The most common side effects of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution include:

  • Sleepiness
  • Confusion
  • nausea and vomiting
  • difficulty urinating
  • trouble breathing

These are not all the possible side effects of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

  • Store Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution at room temperature between 68°F to 77°F (20°C to 25°C).
  • Safely throw away medicine that is out of date or no longer needed.
  • Keep Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution and all medicines out of the reach of children.

General information about the safe and effective use of Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution for a condition for which it was not prescribed. Do not give Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution that is written for health professionals.

What are the ingredients in Tussanil DH Tablets (Hydrocodone Tartrate) Oral Solution?

Active ingredients: Tussanil DH Tablets (Hydrocodone Tartrate) Bitartrate and Guaifenesin

Inactive ingredients: artificial raspberry flavor, citric acid, glycerin, methylparaben, potassium citrate, potassium sorbate, propylene glycol, propylparaben, purified water, and saccharin sodium

Manufactured for:

Accelis Pharma, East Windsor, NJ 08520

For more information, go to www.obredon.com or call 1-855-461-5102.

This Medication Guide has been approved by the U.S. Food and Drug Administration Issued: 09/2016

Phenylpropanolamine Hydrochloride:


Tussanil DH Tablets (Phenylpropanolamine Hydrochloride) has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.

Indication: For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.

Tussanil DH Tablets (Phenylpropanolamine Hydrochloride) (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Tussanil DH Tablets (Phenylpropanolamine Hydrochloride) is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing Tussanil DH Tablets (Phenylpropanolamine Hydrochloride), due to an increased risk of hemorrhagic stroke in women who used Tussanil DH Tablets (Phenylpropanolamine Hydrochloride).

Tussanil DH Tablets pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Tussanil DH Tablets available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Tussanil DH Tablets destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Tussanil DH Tablets Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Tussanil DH Tablets pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."PREFERRED PLUS TABTUSSIN (GUAIFENESIN) TABLET [KINRAY]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. Dailymed."PROIN 75 (PHENYLPROPANOLAMINE HYDROCHLORIDE) TABLET, CHEWABLE [PEGASUS LABORATORIES, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  3. Dailymed."CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Tussanil DH Tablets?

Depending on the reaction of the Tussanil DH Tablets after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Tussanil DH Tablets not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Tussanil DH Tablets addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Tussanil DH Tablets, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Tussanil DH Tablets consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 28 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2024 "sdrugs.com". All Rights Reserved